Surface Oncology’s (SURF) Buy Rating Reaffirmed at Cowen

Cowen reissued their buy rating on shares of Surface Oncology (NASDAQ:SURF) in a report released on Thursday morning, AnalystRatings.com reports.

Other analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Surface Oncology from a strong-buy rating to a hold rating in a research report on Wednesday, May 8th. ValuEngine cut shares of Surface Oncology from a buy rating to a hold rating in a research report on Wednesday, May 1st. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $17.63.

Surface Oncology stock opened at $4.22 on Thursday. The firm has a market cap of $120.52 million and a PE ratio of -12.79. Surface Oncology has a fifty-two week low of $3.45 and a fifty-two week high of $18.18.

Surface Oncology (NASDAQ:SURF) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.31. The firm had revenue of $14.43 million for the quarter, compared to analysts’ expectations of $2.50 million. Surface Oncology had a negative net margin of 148.15% and a negative return on equity of 38.09%. As a group, sell-side analysts expect that Surface Oncology will post -1.85 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in the stock. American International Group Inc. grew its holdings in shares of Surface Oncology by 54.3% during the 4th quarter. American International Group Inc. now owns 7,441 shares of the company’s stock valued at $32,000 after purchasing an additional 2,620 shares during the last quarter. California State Teachers Retirement System grew its holdings in shares of Surface Oncology by 19.4% during the 1st quarter. California State Teachers Retirement System now owns 17,724 shares of the company’s stock valued at $85,000 after purchasing an additional 2,877 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Surface Oncology by 8.3% during the 4th quarter. Bank of America Corp DE now owns 88,773 shares of the company’s stock valued at $376,000 after purchasing an additional 6,795 shares during the last quarter. Meeder Asset Management Inc. bought a new position in shares of Surface Oncology during the 4th quarter valued at $30,000. Finally, Rhumbline Advisers bought a new position in shares of Surface Oncology during the 1st quarter valued at $54,000. 59.76% of the stock is currently owned by institutional investors.

About Surface Oncology

Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27.

Featured Article: What is a recession?

Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.